Novo Nordisk A/s

Neurosearch A/s

Klaus Snej Jensen

Svend Treppendahl

Scott E McGraw

Helle Weibel

Frank Wätjen

Brian Frøstrup

This invention relates to novel (1R,2R,3S,5S)-2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane tartrate salts, such as L-tartrate monohydrates and anhydrates, wherein the salts are useful as monoamine neurotransmitter re-uptake inhibitors. Additionally, the invention also relates to the use of these salts in a method for therapy and to pharmaceutical compositions comprising the salts of the invention.

2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane tartrate salts

The present invention provides novel crystalline (&minus;)-3R,4R-trans-7-methoxy-2,2-dimethyl-3-phenyl-4-&lcub;4-&lsqb;2-(pyrrolidin-1-yl)ethoxy&rsqb;phenyl&rcub;chromane, hydrogen maleate useful for reducing or preventing bone loss as well as pharmaceutical compositions containing the same. A process for preparing (&minus;)-3R,4R-trans-7-methoxy-2,2-dimethyl-3-phenyl-4-&lcub;4-&lsqb;2-(pyrrolidin-1-yl)ethoxy&rsqb;phenyl&rcub;chromane, hydrogen maleate is described.

Crystalline(&minus;)-3R,4R-trans-7-methoxy-2,2-dimethyl-3-phenyl-4-&lcub;4-&lsqb;2-(pyrrolidin-1-yl)ethoxy&rsqb;phenyl&rcub;chromane, hydrogen maleate

Therapeutically effective amounts of a 3,4-diarylchroman can be administered transdermally by incorporation of the 3,4-diarylchroman in a matrix or liquid reservoir patch suitable for transdermal delivery, which matrix or liquid reservoir patch optionally contains hydrophobic and/or hydrophilic vehicle(s).

Growing community of inventors

Frederiksberg C, Denmark

Klaus Snej Jensen